Publikationen in Zusammenarbeit mit Forschern von University of British Columbia (63)

2022

  1. A diabetic milieu increases ACE2 expression and cellular susceptibility to SARS-CoV-2 infections in human kidney organoids and patient cells

    Cell Metabolism, Vol. 34, Núm. 6, pp. 857-873.e9

  2. Clinical research in ovarian cancer: consensus recommendations from the Gynecologic Cancer InterGroup

    The Lancet Oncology, Vol. 23, Núm. 8, pp. e374-e384

  3. Early short course of neuromuscular blocking agents in patients with COVID-19 ARDS: a propensity score analysis

    Critical Care, Vol. 26, Núm. 1

  4. IBCL-249 Mosunetuzumab Monotherapy Is an Effective and Well-Tolerated Treatment Option for Patients With Relapsed/Refractory (R/R) Follicular Lymphoma (FL) Who Have Received ≥2 Prior Lines of Therapy: Pivotal Results From a Phase I/II Study

    Clinical Lymphoma, Myeloma and Leukemia, Vol. 22, pp. S387

  5. Impaired Ventilatory Efficiency, Dyspnea, and Exercise Intolerance in Chronic Obstructive Pulmonary Disease Results from the CanCOLD Study

    American Journal of Respiratory and Critical Care Medicine, Vol. 205, Núm. 12, pp. 1391-1402

  6. Lung Spatial Profiling Reveals a T Cell Signature in COPD Patients with Fatal SARS-CoV-2 Infection

    Cells, Vol. 11, Núm. 12

  7. Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study

    The Lancet Oncology, Vol. 23, Núm. 8, pp. 1055-1065

  8. Similar programmed death ligand 1 (PD-L1) expression profile in patients with mild COPD and lung cancer

    Scientific Reports, Vol. 12, Núm. 1